A Conversation With Helena Cowley, CEO of Oxidien Pharmaceuticals

Helena Cowley, MS, MBA, is CEO of UF Innovate | The Hub resident Oxidien Pharmaceuticals, a therapeutics company mitigating kidney stone disease by using enzyme compounds to treat secondary hyperoxaluria. Life Science Nation interviewed Cowley about the early days of Oxidien and how they’ve navigated the fundraising landscape. They discussed conferences, networking, and tools to give early-stage companies an edge when meeting with strategic partners.